Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy- D-glucose and positron emission tomography: An overview of different analytical methods

European Journal of Nuclear Medicine

Volumn 27, Issue 6, 2000, Pages 731-743

  Hoekstra, C J ^a   Paglianiti, I ^b   Hoekstra, O S ^a   Smit, E F ^a   Postmus, P E ^a   Teule, G J J ^a   Lammertsma, A A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b University Hospital   (Italy)

Author keywords

18F 2 fluoro 2 deoxy D glucose; Cancer; Positron emission tomography; Response monitoring

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; CANCER STAGING; COMPARTMENT MODEL; DRUG UPTAKE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034086992     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050570     Document Type: Review

References (109)

1. 1. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
2. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897-916.
3. 18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979; 44: 127-137.
4. 4. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6: 371-388.
5. 5. Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 1980; 238: E69-E82.
6. 6. Ahuja V, Coleman RE, Herndon J, Patz EFJ. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83: 918-924.
7. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9: 1117-1122.
8. 8. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 1999; 40: 591-603.
9. 9. Hoh CK, Schiepers C. 18-FDG imaging in breast cancer. Semin Nucl Med 1999; 29: 49-56.
10. 10. Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998; 78: 521-527.
11. 11. Lucas JD, O'Doherty MJ, Cronin BF, et al. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 1999; 86: 550-556.
12. 12. Maurea S, Mainolfi C, Bazzicalupo L, et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. Am J Roentgenol 1999; 173: 25-29.
13. 13. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest 1997; 112: 1480-1486.
14. 14. Sugawara Y, Zasadny KR, Grossman HB, Francis IR, Clarke MF, Wahl RL. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology 1999; 211: 249-256.
15. 15. Misquitta A, Herman S, Winton T, Burkes R, Shepherd F, Rappaport D. Accuracy of CT in predicting prognosis in patients with non-small cell lung carcinoma after induction chemotherapy. Radiology 1994; 193: 257..
16. 16. Parrat E, Pujol JL, Gautier V, Michel FB, Godard P. Chest tumor response during lung cancer chemotherapy. Computed tomography vs fiberoptic bronchoscopy. Chest 1993; 103: 1495-1501.
17. 17. Pujol JL, Demoly P, Daures JP, Tarhini H, Godard P, Michel FB. Chest tumor response measurement during lung cancer chemotherapy. Comparison between computed tomography and standard roentgenography. Am Rev Respir Dis 1992; 145: 1149-1154.
18. 18. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993; 34: 414-419.
19. 19. Kubota K, Yamada S, Ishiwata K, Ito M, Ido T. Positron emission tomography for treatment evaluation and recurrence detection compared with CT in long-term follow-up cases of lung cancer. Clin Nucl Med 1992; 17: 877-881.
20. 20. Haberkorn U, Ziegler SI, Oberdorfer F, et al. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 1994; 21: 827-834.
21. 21. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995; 36: 1625-1632.
22. 22. Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996; 23: 941-946.
23. 18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323-1329.
24. 24. Herholz K, Pietrzyk U, Voges J, et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 1993; 79: 853-858.
25. 25. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988; 61: 1776-1778.
26. 26. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33: 325-329.
27. 27. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-1980.
28. 28. Craft PS, Harris AL. Clinical prognostic significance of tumour angiogenesis. Ann Oncol 1994; 5: 305-311.
29. 29. Hunter GJ, Hamberg LM, Choi N, Jain RK, McCloud T, Fischman AJ. Dynamic T1-weighted magnetic resonance imaging and positron emission tomography in patients with lung cancer: correlating vascular physiology with glucose metabolism. Clin Cancer Res 1998; 4: 949-955.
30. 11C]deoxyglucose. J Cereb Blood Flow Metab 1985; 5: 179-192.
31. 31. Hasselbalch SG, Madsen PL, Knudsen GM, Holm S, Paulson OB. Calculation of the FDG lumped constant by simultaneous measurements of global glucose and FDG metabolism in humans. J Cereb Blood Flow Metab 1998; 18: 154-160.
32. 32. Burk D, Woods M, Hunter J. On the significance of glucolysis for cancer growth, with special reference to Morris rat hepatomas. J Natl Cancer Inst 1967; 38: 839-863.
33. 33. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 1811-1817.
34. 34. Smith TA. FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun 1998; 19: 97-105.
35. 35. Ahuja V, Coleman RE, Herndon J, Patz EFJ. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83: 918-924.
36. 36. Kraus GE, Bernstein TW, Satter M, Ezzeddine B, Hwang DR, Mantil J. A technique utilizing positron emission tomography and magnetic resonance/computed tomography image fusion to aid in surgical navigation and tumor volume determination. J Image Guid Surg 1995; 1: 300-307.
37. 37. Gross MW, Weber WA, Feldmann HJ, Bartenstein P, Schwaiger M, Molls M. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 1998; 41: 989-995.
38. 38. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999; 40: 556-565.
39. 39. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol 1998; 25: 317-322.
40. 40. Fanciulli M, Paggi MG, Bruno T, et al. Glycolysis and growth rate in normal and in hexokinase-transfected NIH-3T3 cells. Oncol Res 1994; 6: 405-409.
41. 41. Arora KK, Fanciulli M, Pedersen PL. Glucose phosphorylation in tumor cells. Cloning, sequencing, and overexpression in active form of a full-length cDNA encoding a mitochondrial bindable form of hexokinase. J Biol Chem 1990; 265: 6481-6488.
42. 42. Hautzel H, Muller-Gartner HW. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 1997; 38: 1384-1386.
43. 43. Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991; 32: 1655-1660.
44. 44. De Witte O, Hildebrand J, Luxen A, Goldman S. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 1994; 74: 2836-2842.
45. 45. Haberkorn U, Reinhardt M, Strauss LG, et al. Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy. J Nucl Med 1992; 33: 1981-1987.
46. 46. Rozental JM, Levine RL, Nickles RJ, Dobkin JA. Glucose uptake by gliomas after treatment. A positron emission tomographic study. Arch Neurol 1989; 46: 1302-1307.
47. 47. Takikawa S, Dhawan V, Spetsieris P, et al. Noninvasive quantitative fluorodeoxyglucose PET studies with an estimated input function derived from a population-based arterial blood curve. Radiology 1993; 188: 131-136.
48. 48. Messa C, Choi Y, Hoh CK, et al. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr 1992; 16: 684-689.
49. 18F]fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin. J Comput Assist Tomogr 1993; 17: 115-123.
50. 50. Avril N, Bense S, Ziegler SI, et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med 1997; 38: 1186-1191.
51. 18F-fluoro-2-deoxyglucose, the Patlak method, and an image-derived input function. J Cereb Blood Flow Metab 1998; 18: 716-723.
52. 52. Ohtake T, Kosaka N, Watanabe T, et al. Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. J Nucl Med 1991; 32: 1432-1438.
53. 53. Sandell A, Ohlsson T, Erlandsson K, Strand SE. An alternative method to normalize clinical FDG studies. J Nucl Med 1998; 39: 552-555.
54. 54. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-4471.
55. 55. Germano G, Chen BC, Huang SC, Gambhir SS, Hoffman EJ, Phelps ME. Use of the abdominal aorta for arterial input function determination in hepatic and renal PET studies. J Nucl Med 1992; 33: 613-620.
56. 56. Hoekstra C, Hoekstra O, Lammertsma AA. On the use of image derived input functions in oncological FDG PET studies. Eur J Nucl Med 1999; 26: 1489-1492.
57. 57. Spence AM, Muzi M, Graham MM, et al. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. J Nucl Med 1998; 39: 440-448.
58. 58. Wiggers H, Bottcher M, Nielsen TT, Gjedde A, Botker HE. Measurement of myocardial glucose uptake in patients with ischemic cardiomyopathy: application of a new quantitative method using regional tracer kinetic information. J Nucl Med 1999; 40: 1292-1300.
59. 59. Botker HE, Goodwin GW, Holden JE, Doenst T, Gjedde A, Taegtmeyer H. Myocardial glucose uptake measured with fluorodeoxyglucose: a proposed method to account for variable lumped constants. J Nucl Med 1999; 40: 1186-1196.
60. 60. Langen KJ, Braun U, Rota KE, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993; 34: 355-359.
61. 61. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 1993; 34: 1-6.
62. 62. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography. 1. Effect of object size. J Comput Assist Tomogr 1979; 3: 299-308.
63. 63. Lowe VJ, Hoffman JM, Delong DM, Patz EF, Coleman RE. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994; 35: 1771-1776.
64. 64. Higashi K, Nishikawa T, Seki H, et al. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer. J Nucl Med 1998; 39: 9-15.
65. 65. Ichiya Y, Kuwabara Y, Sasaki M, et al. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med 1996; 10: 193-200.
66. 66. Inokuma T, Tamaki N, Torizuka T, et al. Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med 1995; 36: 229-235.
67. 67. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35: 1308-1312.
68. 68. Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994; 35: 164-167.
69. 69. Schomburg A, Bender H, Reichel C, et al. Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization procedures. Eur J Nucl Med 1996; 23: 571-574.
70. 70. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189: 847-850.
71. 71. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765-770.
72. 72. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992; 182: 185-189.
73. 73. Gupta NC, Frank AR, Dewan NA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992; 184: 441-444.
74. 74. Keyes JWJ. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36: 1836-1839.
75. 75. Kim CK, Gupta NC. Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction. Nucl Med Commun 1996; 17: 890-894.
76. 76. Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology 1992; 183: 643-647.
77. 77. Crown J, Jakubowski A, Kemeny N, et al. A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 1991; 78: 1420-1427.
78. 78. Dacou-Voutetakis C, Palis J, Haidas S, Zannos-Mariolea L, Georgiopoulou P, Matsaniotis N. Abnormal glucose tolerance in children with acute leukemia. Effect of induction chemotherapy including L-asparaginase. Am J Pediatr Hematol Oncol 1983; 5: 139-146.
79. 79. Hozumi Y, Kawano M, Miyata M. Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocr J 1997; 44: 745-749.
80. 80. Sadato N, Tsuchida T, Nakaumra S, et al. Non-invasive estimation of the net influx constant using the standardized uptake value for quantification of FDG uptake of tumours. Eur J Nucl Med 1998; 25: 559-564.
81. 18F]2-fluoro-2-deoxy-D-glucose: a comparison of different analytical methods. J Cereb Blood Flow Metab 1987; 7: 161-172.
82. 82. Hawkins RA, Phelps ME, Huang SC. Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood-brain barrier on the FDG model with and without a vascular compartment: studies in human brain tumors with PET. J Cereb Blood Flow Metab 1986; 6: 170-183.
83. 83. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992; 33: 333-339.
84. 84. Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998; 39: 1002-1007.
85. 18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab 1992; 12: 823-834.
86. 86. Schmidt KC, Lucignani G, Sokoloff L. Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination. J Nucl Med 1996; 37: 394-399.
87. 87. Wu HM, Huang SC, Choi Y, Hoh CK, Hawkins RA. A modeling method to improve quantitation of fluorodeoxyglucose uptake in heterogeneous tumor tissue. J Nucl Med 1995; 36: 297-306.
88. 88. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
89. 18F]fluoro-2-deoxy-D-glucose studies. J Nucl Med 1991; 32: 733-738.
90. 90. Kessler RM, Ellis JRJ, Eden M. Analysis of emission tomographic scan data: limitations imposed by resolution and background. J Comput Assist Tomogr 1984; 8: 514-522.
91. 91. Zasadny KR, Wahl RL. Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images. J Nucl Med 1996; 37: 371-374.
92. 92. Wu HM, Hoh CK, Huang SC, Yao WJ, Phelps ME, Hawkins RA. Quantification of serial tumor glucose metabolism. J Nucl Med 1996; 37: 506-513.
93. 93. Wong WH, Hicks K. A clinically practical method to acquire parametric images of unidirectional metabolic rates and blood spaces. J Nucl Med 1994; 35: 1206-1212.
94. 94. Hunter GJ, Hamberg LM, Alpert NM, Choi NC, Fischman AJ. Simplified measurement of deoxyglucose utilization rate. J Nucl Med 1996; 37: 950-955.
95. 95. Boudraa AE, Champier J, Cinotti L, Bordet JC, Lavenne F, Mallet JJ. Delineation and quantitation of brain lesions by fuzzy clustering in positron emission tomography. Comput Med Imaging Graph 1996; 20: 31-41.
96. 18F]FDG PET: a clinical validation of statistical parametric mapping. Neuroimage 1999; 9: 63-80.
97. 97. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol 1998; 9: 1193-1198.
98. 98. Gdeedo A, Van Schil P, Corthouts B, Van Mieghem F, Van Meerbeeck J, Van Marck E. Comparison of imaging TNM [(i)TNM] and pathological TNM [pTNM] in staging of bronchogenic carcinoma. Eur J Cardiothorac Surg 1997; 12: 224-227.
99. 99. Langen KJ, Roosen N, Kuwert T, et al. Early effects of intraarterial chemotherapy in patients with brain tumours studied with PET: preliminary results. Nucl Med Commun 1989; 10: 779-790.
100. 100. Ogawa T, Uemura K, Shishido F, et al. Changes of cerebral blood flow, and oxygen and glucose metabolism following radiochemotherapy of gliomas: a PET study. J Comput Assist Tomogr 1988; 12: 290-297.
101. 101. Holthoff VA, Herholz K, Berthold F, et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 1993; 72: 1394-1403.
102. 102. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993; 34: 12-17.
103. 103. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995; 13: 1470-1477.
104. 104. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996; 14: 700-708.
105. 105. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11: 2101-2111.
106. 106. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995; 196: 167-173.
107. 107. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999; 40: 1771-1777.
108. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999; 13:1773-1782.
109. 109. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Med 1998; 4: 1334-1336.